BYRN vs ULBI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BYRN exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a significant divergence between analyst targets and market reality. While the company maintains a strong liquidity position with a current ratio of 4.96 and negligible debt, earnings growth has collapsed by 57.10% YoY. The stock is currently trading above both its Graham Number ($4.87) and Intrinsic Value ($2.52), suggesting it remains overvalued despite the massive price correction. The extreme bearish technical trend and crashing earnings outweigh the optimistic 'Strong Buy' analyst consensus.
ULBI presents a contradictory profile: a stable Piotroski F-Score of 6/9 and strong liquidity are offset by deteriorating profitability and severe earnings misses. While the stock trades attractively on a Price-to-Book (0.99) and Price-to-Sales (0.68) basis, the negative profit margins and a high PEG ratio (3.81) suggest that the recent price surge is disconnected from fundamental earnings growth. The company's stability is anchored by a low Debt/Equity ratio (0.41), but high customer concentration and consistent EPS underperformance create significant risk.
Compare Another Pair
Related Comparisons
BYRN vs ULBI: Head-to-Head Comparison
This page compares Byrna Technologies Inc. (BYRN) and Ultralife Corporation (ULBI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.